SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9244)10/1/2003 10:29:39 AM
From: rkrw  Read Replies (2) of 52153
 
<<I had always been puzzled that MEDI was proposing to cannibalize their own drug - but rkrw pointed out to me recently that MEDI only has 50% of Synagis but would have virtually all of Numax (except for the comapratively small AMEV royalty).>>

I'm not sure what % medi shares with abt WW but factor in synagis selling nearly $1B/year before long and there's a strong incentive. It will be a very interesting program to follow as a test case for amev.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News